Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line

doi:10.3748/wjg.14.5403

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3871)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-2) series.

Item

Count

PDF

351

HTML

3177

Figures (1-6)

214

Tables (1-2)

129

Sum=3871

Sep 21, 2008 (publication date) through May 7, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Sep 21, 2008; 14(35): 5403-5411
Published online Sep 21, 2008. doi: 10.3748/wjg.14.5403

Full Size Figure Download Figure

Figure 5 Expression of EGFR and the blood vessel endothelial cells in different treatment group in BxPC-3 mouse xenograft tissues. IHC was used to determine expression levels of EGFR and evaluate tumor microvessel density. A: HE staining for each sample (× 400); B: Expression of EGFR in treatment group was decreased compared with the control (× 400); C: Microvessel density of erlotinib treated group was lower than that of the control group.

Citation: Lu YY, Jing DD, Xu M, Wu K, Wang XP. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol 2008; 14(35): 5403-5411
URL: https://www.wjgnet.com/1007-9327/full/v14/i35/5403.htm
DOI: https://dx.doi.org/10.3748/wjg.14.5403